argenx to Present at Upcoming Investor Conferences

argenx to Present at Upcoming Investor Conferences


May 27, 2026Amsterdam, the Netherlands argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in June:

  • William Blair 46th Annual Growth Stock Conference. Presentation on Wednesday, June 3, 2026 at 12:40 p.m. CT in Chicago, IL.
  • Goldman Sachs 47th Annual Global Healthcare Conference. Fireside chat on Tuesday, June 9, 2026 at 4:00 p.m. ET in Miami, FL.

A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit  www.argenx.com  and follow us on LinkedIn, Instagram, Facebook, and YouTube.

Contacts

Media:

Ben Petok
bpetok@argenx.com

Investors:

Alexandra Roy
aroy@argenx.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ARGX
The Conversation (0)
GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications

GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications

KELOWNA, BC / ACCESS Newswire / October 6, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is providing this strategic update.Lexaria's DehydraTECHâ„¢ technology is currently being evaluated both by Lexaria and... Keep Reading...
BriaCell Therapeutics (TSX:BCT)

BriaCell’s Bria-ABC Joins Roster of US-Enrolled Breast Cancer Trials

BriaCell Therapeutics’ (TSX:BCT,NASDAQ:BCTX) Phase 3 Bria-ABC study has been included in a roundup of breast cancer clinical trials currently enrolling in the US, published by cancer publication CURE.In its September 24 article, CURE enumerated seven studies spanning early-stage to heavily... Keep Reading...
Lexaria Updates Financial Position

Lexaria Updates Financial Position

KELOWNA, BC / ACCESS Newswire / September 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is providing the following update.Lexaria is in a strong cash position following both its recently announced Australian tax... Keep Reading...
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

KELOWNA, BC / ACCESS Newswire / September 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today closed its previously announced exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the... Keep Reading...
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

KELOWNA, BC / ACCESS Newswire / September 8, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to... Keep Reading...
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

KELOWNA, BC / ACCESS Newswire / September 4, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September... Keep Reading...

Interactive Chart

Latest Press Releases

Related News